Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 5Carcinoma, Renal Cell 5Neuroendocrine Tumors 1Multiple Myeloma 1Lymphoma, Follicular 1Liver Neoplasms 1Carcinoma, Hepatocellular 1Adult Solid Neoplasm 1

Interventions

temsirolimus 2Sirolimus 2AZD 6244 2ARQ 197 2veliparib 1sargramostim 1pegfilgrastim 1ixabepilone 1cixutumumab 1belinostat 1Vorinostat 1Topotecan 1Tolbutamide 1Taxes 1Sunitinib 1Rifampin 1Paclitaxel 1Omeprazole 1Midazolam 1Ketoconazole 1Isotretinoin 1Irinotecan 1Introns 1Interferon alpha-2 1Hydroxychloroquine 1Gemcitabine 1Erlotinib Hydrochloride 1Epothilones 1Dextromethorphan 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adult Solid Neoplasm × Introns × Clear all
NCT00217373 2015-04-20

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

National Cancer Institute (NCI)

Phase 1 Completed
33 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡